Announcements Trials
Browse Landscape

Phase

Phase 2 65Phase 3 55Phase 1 36Phase 1/2 22Phase 4 2Phase 2/3 2

Status

Completed 2

Sponsor Class

OTHER 9OTHER_GOV 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Bortezomib × Clear all
NCT02268890 2016-07-11

A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma

Johnson & Johnson Taiwan Ltd

Phase 4 Completed
18 enrolled
Plasma cell

Multiple Myeloma

NCT00257114 2008-02-11

Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability

Millennium Pharmaceuticals, Inc.

Phase 4 Completed
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡